The NIH is exploring the dual potential of GLP-1 drugs, positing that they not only reduce weight but may also substantially decrease cravings for addictive substances, such as alcohol.
Researchers are conducting randomized clinical trials with participants at a cocktail bar setup to study cravings ethically and in real-time, seeking to understand the full benefits of semaglutide.
GLP-1 receptor agonists may offer additional health benefits beyond weight loss. They are being investigated for their effects on cardiovascular health, chronic illnesses, and even neurodegenerative disorders.
There’s an expansive interest in GLP-1 drugs as they are tested for their therapeutic potentials across a spectrum of diseases, suggesting a paradigm shift in treatment methodologies.
Collection
[
|
...
]